Floatz logo

Darovasertib

Uveal Melanoma

IDEAYA BiosciencesSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

60 Active assets in the Uveal Melanoma cohort.

Asset / SponsorPhaseRating
Ifa
Craig L Slingluff, Jr
Phase 2BBB
Tyrosinase Peptide
University of Southern California
Phase 3BB
Sargramostim
Thomas Jefferson University
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2/3BB
Gm-Csf
Ahmad Tarhini
Phase 2BB

View all 50 →

Same molecule, other indications

Darovasertib is also rated in:

ocular melanomaActive
B
Indicative · Phase 2
57 / 100
View asset →
cutaneous melanomaActive
CC
Indicative · Phase 1/2
45 / 100
View asset →
colorectal cancerActive
CC
Indicative · Phase 1/2
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →